GlassScriptPhysician profile
Mary Parker Davidson
NPI 1881424380
$1,505.29
in general payments reported to CMS, 2019-2025
20 companies · $1,166 in 2025
The $1,166 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $339 · 2025: $1,166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,320 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,320.30 |
| Education | $184.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $352.73 | 2024-2025 | Adbry |
| Janssen Biotech, INC. | $240.56 | 2024-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $190.70 | 2024-2025 | |
| Galderma Laboratories, L.P. | $176.07 | 2025 | Aklief |
| Abbvie INC. | $72.18 | 2025 | |
| Pfizer INC. | $71.62 | 2025 | |
| Ucb, INC. | $52.20 | 2025 | Bimzelx |
| Incyte Corporation | $44.17 | 2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $39.56 | 2025 | Cabtreo |
| Almirall LLC | $30.60 | 2025 | Klisyri |
| Mayne Pharma Commercial LLC | $29.86 | 2024 | |
| Mimedx Group, INC. | $25.71 | 2024 | |
| Novartis Pharmaceuticals Corporation | $25.16 | 2025 | |
| Journey Medical Corporation | $24.66 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $22.65 | 2025 | Dupixent |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $22.02 | 2024 | Zoryve |
| Biofrontera INC. | $22.01 | 2025 | Ameluz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.32 | 2025 | Spevigo |
| Lnhc, INC | $21.07 | 2025 | Zelsuvmi |
| Lilly USA, LLC | $20.44 | 2024 | Ebglyss, Taltz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Davidson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.